Skip to main content
. 2016 Mar 7;95(9):e3000. doi: 10.1097/MD.0000000000003000

FIGURE 1.

FIGURE 1

MR images of a 37-year-old woman with invasive ductal carcinoma whose recurrence occurred in the ipsilateral portion of the breast 17 months after NAC initiation. (A) Pre-NAC MR image acquired in the subtracted early postcontrast phase shows a marked BPE and an 8.7-cm nonmass enhancement involving the left lower outer breast (arrow). (B) Post-NAC MR image acquired in the subtracted early postcontrast phase shows that the BPE decreased to the minimal grade and that the nonmass enhancement also decreased in size and volume (arrow). Initial surgical histopathology findings yielded an HER2-enriched type of invasive ductal carcinoma 0.2 cm in size. Seventeen months later, a 1.2-cm linear nonmass enhancement was detected on a subtraction image of a screening MRI, (C) and it was confirmed to be a 0.8-cm ductal carcinoma in situ upon subsequent breast surgery. BPE = background parenchymal enhancement, MR = magnetic resonance, MRI = magnetic resonance imaging, NAC = neoadjuvant chemotherapy, HER2 = human epidermal growth factor receptor 2.